Skip to main content

14-06-2020 | Haematology | Video

EHA25 | Comparable outcomes with first-line azacitidine, decitabine in geriatric AML patients

Amer Zeidan reports on their analysis of ASTRAL-1 trial data indicating that both azacitidine and decitabine are valid options for geriatric patients with treatment-naïve acute myeloid leukaemia (6:25).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits